What happened
FDA describes how it evaluates pharmaceutical manufacturers through risk-based surveillance inspections and for-cause inspections. Observations may be documented on Form FDA 483, which does not represent a final agency determination; companies generally have 15 business days to provide a voluntary response. FDA reviews inspection reports, evidence, company responses, regulatory requirements, technical standards, facility profiles and patient risk before classifying inspections as no action indicated, voluntary action indicated or official action indicated. For CGMP deficiencies, FDA may use warning or untitled letters, regulatory meetings, recalls, import alerts, injunctions, seizures or criminal prosecution. OAI classifications may also affect application approvals, export documentation and government contracts.
Why it matters
From a pharmaceutical manufacturing perspective, the page highlights the importance of maintaining CGMP compliance, preparing for both surveillance and for-cause inspections, and responding promptly to documented observations. Manufacturers may need comprehensive corrective and preventive actions to address deficiencies, particularly because FDA generally changes an OAI classification only after those actions are implemented and verified through an onsite follow-up inspection. Inspection outcomes may affect product supply, pending applications, exports and facility operations.
Key topics: Risk-based CGMP inspections, FDA inspection classifications, Compliance and enforcement actions